COMMUNIQUÉS West-GlobeNewswire

Cuprina Reaffirms Commitment to Shareholders and Patients Following Recent Stock Market Activity
18/08/2025
Singapore, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited ( Nasdaq: CUPR ) (“ Cuprina ” or “ the Company ”) issued the following statement in response to recent unusual trading activity and [...]
OncoC4 Strengthens Leadership Team with Appointment of Shiniu Wei as Chief Financial Officer
18/08/2025
ROCKVILLE, Md., Aug. 18, 2025 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer today announced the appointment of Shiniu Wei as Chief Financial Officer (CFO [...]
Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt
18/08/2025
Retired all principal and accrued interest owed its two senior secured lenders, Resorts World Inc. Pte. Ltd., or RWI, and C.V. Starr and Co., Inc., eliminating all senior secured debt from its balance sheet. Entered [...]
Catheter Precision Receives Approval for LockeT in the United Kingdom
18/08/2025
FORT MILLS, S.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac [...]
Synergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor® Focus + Energy
18/08/2025
EG America, 6th Largest U.S. Convenience Chain, Bolstering 1,600+ High-Traffic Locations Nationwide WESTBROOK, Maine, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a [...]
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
18/08/2025
Company expects to complete BLA submission in the fourth quarter of 2025 NOVATO, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the initiation of a rolling [...]
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
18/08/2025
-- Filings both for the obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination submitted to EMA by our partner, Menarini, for treatment of adults with primary hypercholesterolemia (heterozygous [...]
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
18/08/2025
– Phase 1/2 trial expected to initiate in 2H 2025 in patients with BEST1 inherited retinal disease RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD), a clinical-stage [...]
Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
18/08/2025
Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025 Strong physician response following successful launch of ZELSUVMI™ (berdazimer) [...]
Legend Biotech Appoints Carlos Santos as Chief Financial Officer
18/08/2025
SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company’s Chief [...]
LIXTE Biotechnology Holdings Provides Corporate Update
18/08/2025
-Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory Committee- - Reports [...]
Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases
18/08/2025
· Collaboration strengthens Boehringer’s pipeline in Eye Health. · Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an unmet need. · Melanocortin [...]
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update
18/08/2025
NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet medical need. [...]
Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.
18/08/2025
Extrovis AG Bahnhof Park 4 6340, Baar, Switzerland Media Relations Contact Madhu Marur madhu.marur@extrovis.com Press Release Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC ( [...]
Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue
18/08/2025
HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled “Composition and Method of [...]
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
18/08/2025
SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief [...]
NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
18/08/2025
FDA Clearance Further Validates Technology Platform and Offers Alternatives to Pharmaceutical and Invasive Surgical Treatments EDEN PRAIRIE, Minn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies [...]
Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy
18/08/2025
ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today [...]
Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
18/08/2025
August 18, 2025 Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Opportunity to be First Mover in $7.3Bn Addressable Market Biodexa Pharmaceuticals [...]

Pages